ClinicalTrials.gg
CompletedNCT04806711MCOS11Updated Mar 19, 2021

Eleven Years of Menicon Z Night Contact Lens Wear in Reducing Myopia Progression in Children

An interventional study of Menicon Z Night and Control in Myopia, Progressive and Children, Only, sponsored by Menicon Co., Ltd.. Completed. Open to participants aged 6 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-19.

Sponsored by Menicon Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 14 years after the study started (first participant enrolled Mar 2007, registered Mar 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
6 Years to 12 Years
Sex
All
01

Study summary

To compare axial length growth of white European myopic children wearing Menicon Z Night orthokeratology contact lenses to a control group of distance, single-vision glasses and contact lenses over an 11-year period.

Read the detailed description

This prospective, controlled, parallel, longitudinal study compared the axial length growth of white European myopic children wearing Menicon Z Night orthokeratology contact lenses to a control group of distance, single-vision glasses and or distance, single-vision soft contact lenses over an 11-year period.

02

Conditions studied

  • Myopia, Progressive
  • Children, Only

Browse trials for

03

In context

Myopia, Degenerative

71 studies on the registry are indexed under Myopia, Degenerative; 20 are open to participants now.

This study's enrollment of 20 is below the median of 122 across 57 interventional studies indexed under Myopia, Degenerative.

Browse Myopia, Degenerative studies →

Lead sponsor

Menicon Co., Ltd. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be 6 to 12 years of age, both ages inclusive
  • A low-to-moderate level of myopia (between 0.75 and 4.00 D) and of astigmatism (≤ 1.00 D)
  • Neophyte contact lens wearer
  • Be successfully fitted with spectacles or orthokeratology contact lenses
  • Be able to achieve, through spherical refraction correction, a logMAR visual acuity of 0.8 or better in each eye
  • Be willing and able to follow the subject instructions and to meet the protocol-specified schedule of follow-up visits
  • White European ethnicity

Exclusion criteria

Exclusion Criteria:

  • Systemic or ocular disease affecting ocular health
  • Use of any systemic or topical medications that could affect ocular physiology or contact lens performance
  • Any lid or anterior segment abnormalities for which contact lens wear could be
  • CCLRU grade ≥ 2 for any given anterior segment ocular clinical signs
  • Aphakic, amblyopic, and atopic individuals
  • Refractive astigmatism ≥ ½ spherical refraction
  • Previous contact lens wear
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Menicon Z Night

    The experimental arm consist of a group of Menicon Z Night orthokeratology contact lens wearers

    Device: Menicon Z Night

  • Active comparator
    Control

    The active comparator arm consist of a control group of distance, single-vision glasses and contact lens wearers

    Device: Control

Interventions

  • DeviceMenicon Z Night

    Menicon Z Night orthokeratology contact lenses were used to assess their efficacy in reducing myopia progression in children

  • DeviceControl

    Distance, single-vision glasses were used as a control

06

What researchers measure

Primary outcomes

  1. Axial length

    To compare axial length growth of white European myopic children wearing Menicon Z Night orthokeratology contact lenses to a control group of distance, single-vision glasses and soft contact lens wearers. Measurements of axial length were taken with the Zeiss IOLMaster (Carl Zeiss Jena GmbH, Jena, Germany). Three separate measurements of axial length were recorded per subject and per visit, and a mean obtained.

    Time frame: 11 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutierrez-Ortega R. Myopia control with orthokeratology contact lenses in Spain: refractive and biometric changes. Invest Ophthalmol Vis Sci. 2012 Jul 31;53(8):5060-5. doi: 10.1167/iovs.11-8005. PubMed 22729437 ↗
  • Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutierrez-Ortega R, Sugimoto K. Long-term Efficacy of Orthokeratology Contact Lens Wear in Controlling the Progression of Childhood Myopia. Curr Eye Res. 2017 May;42(5):713-720. doi: 10.1080/02713683.2016.1221979. Epub 2016 Oct 21. PubMed 27767354 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2007 to primary completion in Mar 2018, 132 months.

Of 30 interventional studies with no phase under Myopia, Degenerative, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 96. This study's 132 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2021
First posted
Mar 19, 2021
StartActual
Mar 1, 2007
Primary completionActual
Mar 1, 2018
CompletionActual
Mar 1, 2018
Last update
Mar 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04806711
Lead sponsor
Menicon Co., Ltd.
Collaborators
Universidad Europea de Madrid, Clinica novovision
Responsible party
Sponsor
First posted
Mar 19, 2021
Start date
Mar 1, 2007
Primary completion
Mar 1, 2018
Completion
Mar 1, 2018
Last update
Mar 19, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion